BRC News

A rapid brain imaging protocol for the diagnosis and monitoring of the disease would make it possible to acquire scans in just five minutes instead of 20 to 30 minutes.

New technology could make health research more efficient and faster, according to results from a live pilot study.

NIne out of ten research participants would do it again, according to the latest patient research experience survey.

Researchers can apply for one of 8 stalls at a community researach engagement event and for up to £500 to develop an interactive activity.

Researchers and people living with Parkinson’s have produced new information booklets for clinicians and patients to support easier conversations about Parkinson’s dementia.

New machine learning technology can use real-time A&E data to predict how many patients will need an emergency bed later that day and in which part of the hospital.

The trial results are good news for non-small cell lung cancer patients who are not eligible for standard of care platinum-based chemotherapy.

A new collaboration hosted at UCLH to research patient safety and a new BRC theme in critical and perioperative care have been launched.

As the NHS turns 75, our Managing Director Dr Nick McNally reflects on his career in NHS research, why research matters, and more.

A new digital health hub at UCL backed by the BRC will bring together a team to better deploy digital technologies in the fight against antimicrobial resistance across humans, animals and the environment.

Quell Therapeutics, a UCL spinout that develops cell engineering technology to treat autoimmune diseases, is to collaborate with biopharmaceutical giant AstraZeneca in a deal worth over $2billion (£1.6bn).

Testing for NHS staff effectively detected COVID-19 infections that would have otherwise been missed.

Lesbian, gay and bisexual people are more than twice as likely than their straight peers to experience suicidal thoughts or self-harming behaviours, finds a new study led by UCL researchers.

Third dose COVID-19 booster vaccines offer lasting protection after several months, according to a nationwide trial.

Research has identified a new compound that can stimulate nerve regeneration after injury, as well as protect cardiac tissue from the sort of damage seen in heart attack.